Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy.

Reyner E, Lum B, Jing J, Kagedal M, Ware JA, Dickmann LJ.

Clin Transl Sci. 2020 Mar;13(2):410-418. doi: 10.1111/cts.12726. Epub 2019 Dec 12.

2.

Can Digital Health Enable Higher Quality Real-World Evidence-Based Decisions?

Dickmann LJ, Kothare PA.

Clin Pharmacol Ther. 2019 Jul;106(1):45-46. doi: 10.1002/cpt.1440. Epub 2019 Apr 23. No abstract available.

PMID:
31013352
3.

Racial and Ethnic Composition of Cancer Clinical Drug Trials: How Diverse Are We?

Dickmann LJ, Schutzman JL.

Oncologist. 2018 Feb;23(2):243-246. doi: 10.1634/theoncologist.2017-0237. Epub 2017 Dec 19.

4.

Pharmacogenomics in the age of personalized medicine.

Dickmann LJ, Ware JA.

Drug Discov Today Technol. 2016 Sep - Dec;21-22:11-16. doi: 10.1016/j.ddtec.2016.11.003. Review.

PMID:
27978982
5.

Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1.

Foti RS, Isoherranen N, Zelter A, Dickmann LJ, Buttrick BR, Diaz P, Douguet D.

J Pharmacol Exp Ther. 2016 May;357(2):281-92. doi: 10.1124/jpet.116.232637. Epub 2016 Mar 2.

6.

Evaluation of Fluorophotometry to Assess the Vitreal Pharmacokinetics of Protein Therapeutics.

Dickmann LJ, Yip V, Li C, Abundes J Jr, Maia M, Young C, Stainton S, Hass PE, Joseph SB, Prabhu S, Boswell CA.

Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6991-9. doi: 10.1167/iovs.15-17457.

PMID:
26513505
7.

IL-22 regulates iron availability in vivo through the induction of hepcidin.

Smith CL, Arvedson TL, Cooke KS, Dickmann LJ, Forte C, Li H, Merriam KL, Perry VK, Tran L, Rottman JB, Maxwell JR.

J Immunol. 2013 Aug 15;191(4):1845-55. doi: 10.4049/jimmunol.1202716. Epub 2013 Jul 8.

8.

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.

Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L.

Drug Metab Dispos. 2013 Sep;41(9):1598-609. doi: 10.1124/dmd.113.052225. Epub 2013 Jun 21. Review.

PMID:
23792813
9.

Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes.

Konopnicki CM, Dickmann LJ, Tracy JM, Tukey RH, Wienkers LC, Foti RS.

Arch Biochem Biophys. 2013 Jul 15;535(2):143-9. doi: 10.1016/j.abb.2013.03.012. Epub 2013 Apr 4.

10.

Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia.

Wang Z, Lin YS, Dickmann LJ, Poulton EJ, Eaton DL, Lampe JW, Shen DD, Davis CL, Shuhart MC, Thummel KE.

J Bone Miner Res. 2013 May;28(5):1101-16. doi: 10.1002/jbmr.1839.

11.

Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy.

Dickmann LJ, Isoherranen N.

Drug Metab Dispos. 2013 Feb;41(2):270-4. doi: 10.1124/dmd.112.047118. Epub 2012 Jul 19.

PMID:
22815312
12.

In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties.

Dickmann LJ, VandenBrink BM, Lin YS.

Drug Metab Dispos. 2012 Jul;40(7):1263-7. doi: 10.1124/dmd.112.044909. Epub 2012 Apr 24.

PMID:
22531045
13.

Effects of interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture.

Dickmann LJ, Patel SK, Wienkers LC, Slatter JG.

Curr Drug Metab. 2012 Sep 1;13(7):930-7.

PMID:
22475267
14.

Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression.

Dickmann LJ, McBride HJ, Patel SK, Miner K, Wienkers LC, Slatter JG.

Biochem Pharmacol. 2012 Jun 15;83(12):1682-9. doi: 10.1016/j.bcp.2012.03.001. Epub 2012 Mar 10.

PMID:
22425536
15.

An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway.

Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE.

Mol Pharmacol. 2012 Apr;81(4):498-509. doi: 10.1124/mol.111.076356. Epub 2011 Dec 28.

16.

Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture.

Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG.

Drug Metab Dispos. 2011 Aug;39(8):1415-22. doi: 10.1124/dmd.111.038679. Epub 2011 May 9.

PMID:
21555507
17.

Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.

Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, Nelson WL, Isoherranen N.

Biochem Pharmacol. 2009 Jan 15;77(2):258-68. doi: 10.1016/j.bcp.2008.10.012. Epub 2008 Oct 17.

18.

Re-engineering of CYP2C9 to probe acid-base substrate selectivity.

Tai G, Dickmann LJ, Matovic N, DeVoss JJ, Gillam EM, Rettie AE.

Drug Metab Dispos. 2008 Oct;36(10):1992-7. doi: 10.1124/dmd.108.022186. Epub 2008 Jul 7.

19.

Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening.

McLaughlin LA, Dickmann LJ, Wolf CR, Henderson CJ.

Drug Metab Dispos. 2008 Jul;36(7):1322-31. doi: 10.1124/dmd.108.021261. Epub 2008 Apr 17.

PMID:
18420780
20.

Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy.

Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF, Isoherranen N.

Biochem Pharmacol. 2008 Apr 15;75(8):1677-87. doi: 10.1016/j.bcp.2008.01.012. Epub 2008 Feb 7.

21.

Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.

Foti RS, Dickmann LJ, Davis JA, Greene RJ, Hill JJ, Howard ML, Pearson JT, Rock DA, Tay JC, Wahlstrom JL, Slatter JG.

Xenobiotica. 2008 Mar;38(3):264-80. doi: 10.1080/00498250701802514 .

PMID:
18274956
22.

Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates.

Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, Rock DA.

Chem Res Toxicol. 2007 Dec;20(12):1778-86. Epub 2007 Nov 15.

PMID:
18001057
23.

Differential activation of CYP2C9 variants by dapsone.

Hummel MA, Dickmann LJ, Rettie AE, Haining RL, Tracy TS.

Biochem Pharmacol. 2004 May 15;67(10):1831-41.

PMID:
15130760
24.

CYP2C9 genetic polymorphisms and warfarin.

Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY.

Clin Appl Thromb Hemost. 2004 Apr;10(2):149-54.

PMID:
15094935
25.

Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.

Dickmann LJ, Locuson CW, Jones JP, Rettie AE.

Mol Pharmacol. 2004 Apr;65(4):842-50.

PMID:
15044613
26.

Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.

Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ.

Drug Metab Dispos. 2002 Apr;30(4):385-90.

PMID:
11901091
27.

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.

Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI.

Mol Pharmacol. 2001 Aug;60(2):382-7.

PMID:
11455026
28.

Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.

Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr.

J Clin Pharmacol. 2001 Jul;41(7):715-22.

PMID:
11452703
29.

Characterization of eight new members of the calmodulin-like domain protein kinase gene family from Arabidopsis thaliana.

Hrabak EM, Dickmann LJ, Satterlee JS, Sussman MR.

Plant Mol Biol. 1996 May;31(2):405-12.

PMID:
8756605

Supplemental Content

Loading ...
Support Center